With a market capitalization (market cap) of $1.54B — a measure of how much the company is worth — Rapport Therapeutics, Inc. Common Stock ranks #2,221 among the 2,510 companies tracked, and 295th in Healthcare as of October 3, 2026. Shares trade at $32.17, down 2.01% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.53B | +6.56% | $32.17 |
| 2025 | Dec 31, 2025 | $1.43B | +318.84% | $30.34 |
| 2024 | Dec 31, 2024 | $342.17M | — | $17.74 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.54B as of October 3, 2026.
Rapport Therapeutics, Inc. Common Stock's ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $32.17 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.53B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 46,978,223 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity).
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) is worth $1.54B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Rapport Therapeutics, Inc. Common Stock’s book equity is about $484.65M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $1.54B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Rapport Therapeutics, Inc. Common Stock ranks #2,221 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #295 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2218 | ConnectOne Bancorp, Inc. CNOB | $1.55B | +1.45% |
| #2219 | Alphatec Holdings, Inc. ATEC | $1.54B | +1.31% |
| #2220 | Tecnoglass Inc. TGLS | $1.54B | -0.88% |
| #2222 | Companhia Siderúrgica Nacional SID | $1.54B | +3.57% |
| #2223 | Hawaiian Electric Industries, Inc. HE | $1.54B | -0.34% |
| #2224 | United Parks & Resorts Inc. PRKS | $1.53B | +4.11% |
Rapport Therapeutics, Inc. Common Stock’s ranking market cap of $1.54B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 46,978,223. The historical market-cap series last observed $1.53B on October 2, 2026.
Over the past year, Rapport Therapeutics, Inc. Common Stock’s market cap is up 13.91%, using historical market-cap records rather than today’s share count applied to past prices.
Rapport Therapeutics, Inc. Common Stock (RAPP) shares trade at $32.17, down 2.01% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.